Drug Profile
Research programme: anticancer therapeutics - Roche/Epitome
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Epitomics; Roche
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Aug 2010 Epitomics spins-off a new company called Apexigen
- 20 Oct 2005 Preclinical trials in Cancer in USA (unspecified route)